“Veins first” versus “artery first” approach for management of mixed arterial venous leg ulcers (MAVLU): Systematic review and meta-analysis

医学 荟萃分析 置信区间 随机对照试验 外科 内科学 心脏病学
作者
Mohammed Alagha,Ahmed Alagha,Aoife Lowery,Stewart R. Walsh
出处
期刊:Phlebology [SAGE]
标识
DOI:10.1177/02683555241282118
摘要

Introduction Mixed Arterial and Venous Leg Ulcers (MAVLU) are challenging. The optimal intervention sequence (artery-first vs vein first) is unclear. This review evaluates current evidence on surgical intervention sequencing. Methods MEDLINE, PUBMED, SCOPUS and EMBASE were searched using the term ‘mixed arterial venous leg ulcers.’ Studies were eligible if they reported ulcer healing outcomes in MAVLU patients. Pooled proportions were calculated by random effects modelling. Results The search yielded 606 studies, eight of which contained sufficient data to include in the analysis. There were no randomized controlled trials. Initial modified compression (MCT) and rescue revascularisation in MAVLU with ABI 0.5 to 0.85 achieved a pooled healing rate of 75% (95% CI 69% to 80%) compared to 79% (95% CI 61% to 93%) in patients with standard VLUs. The pooled rescue revascularisation rate for MAVLU patients with moderate arterial disease was 25% (95% CI 6% to 51%). Patients with severe arterial disease (ABI <0.5) who underwent arterial intervention first were less likely to heal (pooled proportion 40%; 95% confidence interval 16% to 66%). No studies compared either MCT or venous ablation with arterial revascularisation as first-line in patients with moderate arterial disease (ABI 0.5 to 0.85) alone or severe arterial disease (ABI <0.5) alone. There was marked heterogeneity between studies with respect to ulcer healing outcomes reported, definitions of ulcer healing, duration and size of ulcers at presentation, use of adjunct procedures such as skin grafting, unit of measurement (legs vs patients) and duration of follow up. Conclusion A ‘veins first’ approach to MAVLU is plausible but robust data are lacking and should be evaluated in a randomized controlled trial.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
华安发布了新的文献求助30
1秒前
1秒前
迟大猫应助dpp采纳,获得10
1秒前
2秒前
astral完成签到,获得积分10
2秒前
科研通AI5应助HJJHJH采纳,获得30
3秒前
Isabel发布了新的文献求助10
3秒前
3秒前
桑姊发布了新的文献求助10
4秒前
4秒前
Cyrus2022完成签到,获得积分10
4秒前
古哉完成签到,获得积分10
4秒前
xiachengcs发布了新的文献求助30
5秒前
炙热芝发布了新的文献求助30
5秒前
Rain完成签到,获得积分10
5秒前
高大的战斗机完成签到,获得积分10
5秒前
26347完成签到 ,获得积分10
5秒前
131343发布了新的文献求助10
5秒前
HZHZ完成签到,获得积分10
5秒前
沈海完成签到,获得积分10
6秒前
6秒前
smartbot发布了新的文献求助20
6秒前
new_vision发布了新的文献求助10
6秒前
英姑应助挽歌采纳,获得10
6秒前
自信富发布了新的文献求助10
7秒前
7秒前
8秒前
NexusExplorer应助包容的幻梅采纳,获得30
8秒前
9秒前
9秒前
Morning发布了新的文献求助10
9秒前
dpp完成签到,获得积分20
10秒前
cat发布了新的文献求助10
10秒前
姚运龙完成签到,获得积分10
10秒前
Jasper应助lost采纳,获得10
10秒前
11秒前
zhaowenxian发布了新的文献求助10
11秒前
11秒前
YULIA完成签到,获得积分10
12秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527723
求助须知:如何正确求助?哪些是违规求助? 3107826
关于积分的说明 9286663
捐赠科研通 2805577
什么是DOI,文献DOI怎么找? 1539998
邀请新用户注册赠送积分活动 716878
科研通“疑难数据库(出版商)”最低求助积分说明 709762